Curis, Inc.
CRISCuris, Inc. in brief
Curis, Inc. is a listed company in the Biotechnology industry, based in Lexington, Massachusetts, USA. Its market value was $5 M on 30 October 2026, which makes it the 26,837th largest listed company in the world and the 4,398th largest in the USA on this site. In the year to December 2025 it had sales of $9 M and a net loss of $8 M. James E. Dentzer is its chief executive. Its shares trade under the symbol CRIS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Curis, Inc.
Curis working to develop innovative and differentiated therapeutics that improve the lives of cancer patients. Headquarters is in USA.
Curis, Inc. timeline
- 2000
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2024
- 💰Record revenue of $11 millionFY2024, the highest of the 8 years on record.
Events of Curis, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,999 (Jan 2020) · #2,496 (Jan 2021) · #3,393 (Jan 2022) · #4,814 (Dec 2022) · #4,425 (Jul 2023) · #3,805 (Jan 2024) · #2,345 (Mar 2026) · #4,143 (Aug 2026) · #4,336 (Oct 2026) · #4,399 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 0.6×
- Price / book
- 1.0×
- Free cash flow yield
- -734.8%
- Net margin
- -80.3%
- Operating margin
- -60.5%
- Return on equity
- -138.8%
- Liabilities / assets
- 72.6%
- Net debt
- $-129M
- Revenue growth
- -13.5%
- R&D / revenue
- 299.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $9M | -13.5% | $-6M | $-8M | -80.3% |
| Dec 2024 | $11M | +8.9% | $-45M | $-43M | -397.7% |
| Dec 2023 | $10M | -1.4% | $-48M | $-47M | -473.2% |
| Dec 2022 | $10M | -4.6% | $-53M | $-57M | -557.8% |
| Dec 2021 | $11M | -1.8% | $-42M | $-45M | -426.7% |
| Dec 2020 | $11M | +8.4% | $-25M | $-30M | -275.9% |
| Dec 2019 | $10M | -4.1% | $-24M | $-32M | -321.4% |
| Dec 2018 | $10M | — | $-29M | $-33M | -312.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-27M | — | — | $-0.58 | — |
| Dec 2024 | $-40M | — | — | $-6.88 | — |
| Dec 2023 | $-38M | $0M | $-38M | $-8.96 | — |
| Dec 2022 | $-54M | $0M | $-55M | $-12.14 | — |
| Dec 2021 | $-38M | $0M | $-38M | $0.50 | — |
| Dec 2020 | $-26M | $1M | $-26M | $-0.61 | — |
| Dec 2019 | $-26M | $0M | $-26M | $-0.97 | — |
| Dec 2018 | $-30M | $0M | $-30M | $-0.98 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-8M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 6, 20268-KCurrent reportListing notice
- Nov 2, 2026DEF 14AProxy statement
- Oct 19, 20268-KCurrent reportMaterial agreement · Unregistered share sale
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 2026424B4IPO prospectus
- Aug 10, 2026S-1IPO registration
- Jul 30, 20268-KCurrent reportListing notice
- Jul 2, 20268-KCurrent reportBylaws amended
- Jul 1, 20268-K/ACurrent report (amended)Bylaws amended
- Jul 1, 20268-KCurrent reportBylaws amended
- Jun 25, 20268-KCurrent reportShareholder vote
- Jun 5, 2026DEF 14AProxy statement
Official filings of Curis, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $9 M
- Operating income
- $-6 M
- Net income
- $-8 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $20 M
- Total liabilities
- $15 M
- Total equity
- $5 M
As of December-2025
Top 28 institutional investors in Curis, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 372,000 | New | 17.80% | $0 M | Nov 16, 2026 |
| 2 | Bleichroeder LP | 190,116 | New | 9.10% | $0 M | Nov 13, 2026 |
| 3 | Dauntless Investment Group, LLC | 100,004 | New | 4.78% | $0 M | Nov 16, 2026 |
| 4 | Nantahala Capital Management, LLC | 93,824 | New | 4.49% | $0 M | Nov 13, 2026 |
| 5 | Morgan Stanley | 87,336 | New | 4.18% | $0 M | Nov 13, 2026 |
| 6 | Cable Car Capital, LP | 66,667 | New | 3.19% | $0 M | Nov 16, 2026 |
| 7 | Two Sigma Investments, LP | 43,931 | New | 2.10% | $0 M | Nov 16, 2026 |
| 8 | HRT Financial LP | 41,445 | New | 1.98% | $0 M | Nov 13, 2026 |
| 9 | Sphera Funds Management LTD. | 39,665 | New | 1.90% | $0 M | Nov 16, 2026 |
| 10 | Vanguard Capital Management LLC | 29,190 | New | 1.40% | $0 M | Nov 13, 2026 |
| 11 | Virtu Financial LLC | 19,771 | New | 0.95% | $0 M | Nov 17, 2026 |
| 12 | Geode Capital Management, LLC | 18,745 | New | 0.90% | $0 M | Nov 6, 2026 |
| 13 | Citadel Advisors LLC | 16,682 | New | 0.80% | $0 M | Nov 16, 2026 |
| 14 | M28 Capital Management LP | 14,244 | New | 0.68% | $0 M | Nov 13, 2026 |
| 15 | FNY Investment Advisers, LLC | 7,685 | New | 0.37% | $0 M | Oct 16, 2026 |
| 16 | Tower Research Capital LLC (TRC) | 7,099 | New | 0.34% | $0 M | Nov 16, 2026 |
| 17 | UBS Group AG | 3,391 | New | 0.16% | $0 M | Nov 10, 2026 |
| 18 | Vanguard Fiduciary Trust Co | 3,083 | New | 0.15% | $0 M | Nov 13, 2026 |
| 19 | BlackRock, Inc. | 1,990 | New | 0.10% | $0 M | Nov 13, 2026 |
| 20 | Steward Partners Investment Advisory, LLC | 129 | New | 0.01% | $0 M | Nov 13, 2026 |
| 21 | Jpmorgan Chase & Co | 89 | New | 0.00% | $0 M | Nov 12, 2026 |
| 22 | Osaic Holdings, Inc. | 75 | New | 0.00% | $0 M | Nov 12, 2026 |
| 23 | Wells Fargo & Company/mn | 71 | New | 0.00% | $0 M | Nov 16, 2026 |
| 24 | BFC Planning, Inc. | 27 | New | 0.00% | $0 M | Nov 13, 2026 |
| 25 | Group One Trading LLC | 22 | New | 0.00% | $0 M | Nov 10, 2026 |
Show all 28: investors 26 to 28
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Jones Financial Companies Lllp | 6 | New | 0.00% | $0 M | Nov 13, 2026 |
| 27 | SBI Securities Co., Ltd. | 6 | -9 (-60.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 28 | Caitong International Asset Management Co., Ltd | 3 | New | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Curis, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 215,599 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 116,491 | $0 M | — | <0.01% | +111% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 96,043 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 17,693 | $0 M | — | <0.01% | +34% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 10,208 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 2,839 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Curis, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Kenneth I. KaitinDirector | Buy | +10,000 | $0.550 | $6 K | 11,407 | Form 4 |
| filed | James E. DentzerPresident & CEO, Director | Conversion | +133,333 | — | — | 148,730 | Form 4 |
| filed | Marc RubinDirector | Conversion | +26,667 | — | — | 28,108 | Form 4 |
| filed | Diantha DuvallCFO | Conversion | +66,666 | — | — | 77,707 | Form 4 |
| filed | Ahmed HamdyCMO | Conversion | +66,667 | — | — | 66,667 | Form 4 |
| filed | Jonathan B. ZungCDO | Conversion | +66,667 | — | — | 66,667 | Form 4 |
| filed | James E. DentzerPresident & CEO, Director | Sell10b5-1 plan | -3,094 | $3.070 | $9 K | 64,877 | Form 4 |
| filed | James E. DentzerPresident & CEO, Director | Sell | -2,406 | $3.180 | $8 K | 67,971 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Curis, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split ; 1-for-20 reverse split ; 1-for-5 reverse split
Trading halts
- 2026-11-04 14:50 UTC, code LUDP, resumed 14:55 UTC
- 2026-11-04 14:45 UTC, code LUDP, resumed 14:50 UTC
- 2026-11-04 14:34 UTC, code LUDP, resumed 14:39 UTC
- 2026-11-03 17:56 UTC, code LUDP, resumed 18:01 UTC
- 2026-11-03 17:49 UTC, code LUDP, resumed 17:54 UTC
Fails to deliver
- : 272,839 shares at $0.55
- : 175,064 shares at $0.45
- : 181,345 shares at $0.40
- : 116,920 shares at $0.38
- : 3,112 shares at $0.39
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Curis, Inc. scorecard#
Passes 4 of the 18 checks that could be worked out: strongest in valuation (2 of 4), weakest in financial health (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.0×Price to book 1.0× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median0.6×Price to sales 0.6× against Biotechnology's median of 8.7×.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-13.5%Revenue down 13.5% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-2.4%-2.4% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-2.4%-2.4% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.58 vs -6.88Diluted EPS -0.58 in fiscal 2025 against -6.88 the year before (report's currency).
- ✓Net income higher than five years earlier-$8 M-$8 M in fiscal 2025 against -$30 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$8 MNet income -$8 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-60.5%-60.5% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-60.5%-60.5% in fiscal 2025 against -521.9% in 2022.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.49 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-88.13Z-score -88.13 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year108.8%Diluted shares up 108.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Curis, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -60.5% | -60.5% | |
| Net margin | -80.3% | -68.9% | |
| Revenue growth, 3 years a year | -2.4% | 12.9% | |
| Revenue growth | -13.5% | 15.8% |
3of 7on the Piotroski tests of financial strength
- Revenue fell 13.5% against the year before.
- Net loss of $8 million, the 17th loss-making year in a row.
- The share count rose 108.8% in the year.
- Liabilities due within a year exceed current assets (current ratio 0.49).
Curis, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 9.4−13.4%100% | 11+8.8%100% | 10−1.4%100% | 10−4.6%100% | 11−1.7%100% | 11+8.3%100% | 10−4.1%100% | 10+5.4%100% | 9.9+31.5%100% | 7.5—100% | |
| Research and development | 28−26.7%299% | 39−2.4%354% | 39−8.7%394% | 43+24.1%426% | 35+51.2%328% | 23+3.4%213% | 22−8.6%223% | 24−45.9%234% | 45+151%456% | 18r32—239% | |
| General and administrative | 14−16.3%149% | 17−10.0%154% | 19−5.1%186% | 20+13.6%193% | 17+42.6%162% | 12+5.0%112% | 12−21.8%116% | 15+5.1%142% | 14−9.8%142% | 16—207% | |
| Total costs and expenses | 42−23.6%448% | 55−5.0%508% | 58−7.6%582% | 63+19.9%622% | 53+47.5%495% | 36+4.0%330% | 34−13.6%343% | 40−33.4%381% | 60−9.0%603% | 66—871% | |
| Operating income | −5.7—−60.5% | −45—−408% | −48—−482% | −53—−522% | −42—−395% | −25—−230% | −24—−243% | −29—−281% | −50—−503% | −58—−771% | |
| Interest and finance income | 0.3−82.1%3.3% | 1.8−39.8%16.2% | 2.9+163%29.3% | 1.1+430%11.0% | 0.2+235%2.0% | 0.1−89.7%0.6% | 0.6−10.2%6.1% | 0.7+33.3%6.6% | 0.5+26.4%5.2% | 0.4—5.4% | |
| Interest expense and finance costs | — | — | — | — | 0—0.0% | 0−100%0.0% | 0.8−79.9%7.9% | 3.9−1.0%37.6% | 4.0+42.8%40.1% | 2.8—36.9% | |
| Other non-operating income (expense) | −1.9−262%−19.8% | 1.2+25.5%10.6% | 0.9—9.2% | −3.7—−35.9% | −3.4—−31.7% | −5.0—−46.2% | −7.8—−77.8% | −3.2—−31.1% | −3.6—−35.9% | −2.4—−31.5% | |
| Income tax | 0—0.0% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −7.6—−80.3% | −43—−398% | −47—−473% | −57—−558% | −45—−427% | −30—−276% | −32—−321% | −33—−312% | −53—−539% | −60—−803% | |
| Earnings per share, basic | -0.58—— | -6.88—— | -8.96—— | -12.14r0.61−2528%— | 0.50r-0.50—— | -0.61—— | -0.97—— | -0.98—— | -1.79r-0.36—— | -0.45—— | |
| Earnings per share, diluted | -0.58—— | -6.88—— | -8.96—— | -12.14r0.61−2528%— | 0.50r-0.50—— | -0.61—— | -0.97—— | -0.98—— | -1.79r-0.36—— | -0.45—— | |
| Shares, weighted average (basic) | 13+109%— | 6.3+19.1%— | 5.3+13.4%— | 4.7r93−94.9%— | 92+88.1%— | 49+46.7%— | 33—— | — | — | — | |
| Shares, weighted average (diluted) | 13+109%— | 6.3+19.1%— | 5.3+13.4%— | 4.7r93−94.9%— | 92+88.1%— | 49+46.7%— | 33+0.2%— | 33+11.0%— | 30r149−77.5%— | 133—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.1−74.7%25.3% | 20−25.1%48.5% | 27+35.7%34.5% | 20−50.9%18.1% | 40−69.1%24.7% | 130+740%63.4% | 15−34.7%44.0% | 24−38.3%63.3% | 38+47.0%51.9% | 26—45.1% | |
| Short-term investments | — | 0−100%0.0% | 30−55.0%38.4% | 66−13.1%60.6% | 76+95.1%46.7% | 39+660%19.0% | 5.1r5.1+706%14.6% | 0.6−97.1%1.7% | 22+19.0%29.7% | 18—31.9% | |
| Receivables | 0−100%0.0% | 3.3+19.9%8.1% | 2.8−6.1%3.6% | 3.0−7.7%2.7% | 3.2+5.9%2.0% | 3.0−6.2%1.5% | 3.2+13.3%9.2% | 2.9−6.8%7.7% | 3.1+25.0%4.2% | 2.5—4.3% | |
| Other current assets | 1.9−39.0%9.3% | 3.0+70.7%7.4% | 1.8−49.4%2.3% | 3.5+7.8%3.2% | 3.3+169%2.0% | 1.2+14.3%0.6% | 1.1+28.5%3.0% | 0.8−16.4%2.2% | 1.0−21.3%1.3% | 1.3—2.2% | |
| Current assets | 6.9−73.8%34.6% | 26−56.7%63.9% | 61−33.9%78.8% | 92−24.7%84.6% | 122−29.2%75.4% | 173+591%84.5% | 25−10.6%71.2% | 28−56.5%74.8% | 64+33.4%87.1% | 48—83.5% | |
| Property, plant and equipment | 0.1−73.2%0.3% | 0.2−46.8%0.6% | 0.4−37.0%0.6% | 0.7+36.4%0.6% | 0.5−23.8%0.3% | 0.7+331%0.3% | 0.2−42.3%0.4% | 0.3−27.0%0.7% | 0.4−11.4%0.5% | 0.4—0.7% | |
| Right-of-use (leased) assets | 1.9−40.2%9.5% | 3.2+3.5%7.7% | 3.1−30.6%4.0% | 4.4−23.4%4.0% | 5.7−12.6%3.5% | 6.6+4315%3.2% | 0.1—0.4% | — | — | — | |
| Goodwill | 9.00.0%45.0% | 9.00.0%21.8% | 9.00.0%11.6% | 9.00.0%8.3% | 9.00.0%5.5% | 9.00.0%4.4% | 9.00.0%25.6% | 9.00.0%24.0% | 9.00.0%12.2% | 9.0—15.6% | |
| Long-term investments | — | — | — | 0−100%0.0% | 24+64.5%14.8% | 15—7.1% | 0—0.0% | — | — | — | |
| Total assets | 20−51.6%100% | 41−46.6%100% | 77−29.0%100% | 109−32.9%100% | 162−20.6%100% | 204+482%100% | 35−6.0%100% | 37−49.4%100% | 74+27.8%100% | 58—100% | |
| Accounts payable | 5.6+85.6%28.1% | 3.0−4.7%7.3% | 3.2−0.7%4.1% | 3.2−50.2%2.9% | 6.4+54.0%4.0% | 4.2−6.7%2.0% | 4.5+53.5%12.7% | 2.9−46.4%7.8% | 5.4−7.8%7.3% | 5.9—10.2% | |
| Debt due within a year | 0−100%0.0% | 7.6−11.1%18.3% | 8.5—11.0% | — | 0−100%0.0% | 0.6—0.3% | 0−100%0.0% | 6.9r6.9+16.9%18.5% | 5.9r5.9+19.8%8.0% | 4.9—8.6% | |
| Current liabilities | 14−26.0%70.5% | 19−13.6%46.1% | 22r14+120%28.5% | 10−25.5%9.2% | 13+33.3%8.3% | 10+54.1%4.9% | 6.5−50.6%18.6% | 13−6.0%35.5% | 14+4.1%19.1% | 14—23.5% | |
| Long-term debt | — | — | — | — | — | 0.3—0.2% | 0−100%0.0% | 29−19.8%76.5% | 36+139%48.3% | 15—25.8% | |
| Lease liabilities (non-current) | 0.4−73.5%2.1% | 1.6+8.7%3.9% | 1.5−46.8%1.9% | 2.8−35.8%2.6% | 4.4−13.5%2.7% | 5.0—2.5% | 0—0.0% | — | — | — | |
| Total liabilities | 15−69.3%72.6% | 47−18.0%115% | 58−7.5%74.5% | 62−13.0%57.2% | 72−2.8%44.1% | 74+6.8%36.1% | 69+64.9%197% | 42−16.0%112% | 50+74.8%67.5% | 28—49.3% | |
| Retained earnings | −1,247—−6248% | −1,240—−3004% | −1,196—−1548% | −1,149—−1056% | −1,092—−673% | −1,047—−512% | −1,017—−2897% | −985—−2636% | −952—−1290% | −899—−1557% | |
| Shareholders' equity | 5.5—27.4% | −6.0−130%−14.5% | 20−57.7%25.5% | 47−48.7%42.8% | 91−30.6%55.9% | 131—63.9% | −34—−96.6% | −4.5−119%−12.0% | 24−18.5%32.5% | 29r29—51.0% | |
| Total liabilities and equity | 20−51.6%100% | 41−46.6%100% | 77−29.0%100% | 109−32.9%100% | 162−20.6%100% | 204+482%100% | 35−6.0%100% | 37−49.4%100% | 74+27.8%100% | 58—100% | |
| Shares outstanding | 0.6r13−92.4%— | 8.5+44.0%— | 5.9+22.0%— | 4.8r97−94.7%— | 92+0.2%— | 92+175%— | 33+0.2%— | 33+1.0%— | 33r164−76.7%— | 141—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.2−16.7%1.8% | 0.2−20.4%1.9% | 0.3+9.4%2.5% | 0.2+47.5%2.3% | 0.2+9.7%1.5% | 0.1+15.2%1.3% | 0.1−29.4%1.2% | 0.2−24.7%1.7% | 0.2+21.8%2.4% | 0.2—2.6% | |
| Share-based compensation | 4.0−32.2%42.6% | 5.9−1.2%54.3% | 6.0−11.1%59.9% | 6.8+27.9%66.4% | 5.3+95.7%49.6% | 2.7+1.5%24.9% | 2.7−32.5%26.6% | 3.9−26.5%37.8% | 5.4+23.9%54.1% | 4.3—57.5% | |
| Cash from operating activities | −27—−288% | −40—−363% | −38—−383% | −54—−535% | −38—−353% | −26—−238% | −26—−262% | −30—−288% | −48—−489% | −36—−476% | |
| Capital expenditure | — | — | 0—0.0% | −0.4—−4.1% | 0—0.0% | −0.7—−6.2% | −0.0—−0.4% | −0.1—−0.8% | −0.2—−1.9% | −0.3—−4.4% | |
| Cash from investing activities | 2.5−91.5%26.5% | 29−22.1%270% | 38+14.4%377% | 33—325% | −48—−450% | −49—−453% | −4.5−121%−44.5% | 21—205% | −3.6−112%−36.7% | 30—400% | |
| Debt issued | — | — | — | — | 0−100%0.0% | 0.9—8.2% | 0—0.0% | — | — | — | |
| Debt repaid | — | — | — | — | 0—0.0% | 0—0.0% | −1.8—−18.2% | −6.1—−58.5% | −5.0—−50.1% | −4.3—−56.8% | |
| Shares issued | 15+27.7%163% | 12−14.8%110% | 14+142%141% | 5.8r5.6—57.5% | 0−100%0.0% | 159—1472% | 0—0.0% | 0−100%0.0% | 42—420% | 0—0.0% | |
| Cash from financing activities | 9.8+184%103% | 3.4−54.7%31.5% | 7.6+774%75.6% | 0.9—8.5% | −4.2−102%−39.2% | 189+711%1743% | 23—233% | −6.0−109%−57.2% | 64—649% | −1.4—−18.1% | |
| Change in cash | −15—−158% | −6.7−196%−61.3% | 6.9—69.2% | −20—−201% | −90−179%−842% | 114—1052% | −7.4—−73.9% | −15−220%−141% | 12—124% | −7.1—−93.7% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | 0−100%— | 0−100%— | 1.1*−66.0%100% | 3.2+8.4%100% | 2.7+8.0%100% | 2.4+14.1%100% | 3.3*+24.1%100% | 2.9—100% | 2.5—100% | 2.1—100% | 2.7*—100% | |
| Research and development | 25−21.7%— | 5.6−13.0%— | 6.7−10.0%— | 6.4−24.5%— | 5.8*−35.0%512% | 6.4−33.8%203% | 7.5−27.3%271% | 8.5−11.2%359% | 9.0*−10.0%268% | 9.7—332% | 10—403% | 9.6—461% | 10.0*—370% | |
| General and administrative | 14−1.3%— | 3.2−13.7%— | 3.2−8.5%— | 5.1+27.3%— | 2.9*−14.0%253% | 3.7−2.7%115% | 3.5−26.4%128% | 4.0−18.5%167% | 3.4*−31.2%100% | 3.8—128% | 4.8—188% | 4.9—234% | 4.9*—181% | |
| Operating expenses | — | 8.7−13.4%— | — | — | — | 10—318% | — | — | — | — | — | — | — | |
| Total costs and expenses | — | — | 9.9−9.6%— | 12−8.1%— | 8.7*−29.4%765% | 10−25.2%318% | 11−26.9%400% | 13−13.9%527% | 12*−17.2%369% | 13—461% | 15—591% | 15—698% | 15*—552% | |
| Operating income | −11—— | −8.7—— | −9.9—— | −12—— | 20*—1724% | −6.9—−218% | −8.3—−300% | −10—−427% | −9.0*—−269% | −11—−361% | −13—−491% | −12—−598% | −12*—−452% | |
| Interest and finance income | 0.2−55.7%— | 0.0−65.0%— | 0.1−32.6%— | 0.1−17.2%— | 0.1*−77.5%4.5% | 0.1−75.4%2.5% | 0.1−86.9%3.3% | 0.1−81.9%3.9% | 0.2*−65.9%6.8% | 0.3—11.1% | 0.7—27.5% | 0.5—24.7% | 0.7*—24.7% | |
| Other non-operating income (expense) | −11—— | 0.6—— | 1.4—— | −13—— | −0.3*—−23.1% | −0.8−269%−25.3% | −0.3−148%−12.4% | −0.5−177%−19.3% | −0.6*−228%−18.7% | 0.5—16.2% | 0.7—27.8% | 0.6—28.4% | 0.5*—18.1% | |
| Net income attributable to shareholders | −22—— | −8.1—— | −8.6—— | −24—— | 19*—1701% | −7.7—−243% | −8.6—−313% | −11—−446% | −9.6*—−288% | −10—−344% | −12—−464% | −12—−569% | −12*—−434% | |
| Earnings per share, basic | — | -1.94—— | -4.02—— | -1.25—— | — | -9.86r-0.49—— | -13.61r-0.68—— | -1.25—— | — | -1.70—— | -2.03—— | -2.05—— | — | |
| Earnings per share, diluted | — | -1.94—— | -4.02—— | -1.25—— | — | -9.86r-0.49—— | -13.61r-0.68—— | -1.25—— | — | -1.70—— | -2.03—— | -2.05—— | — | |
| Shares, weighted average (basic) | 4.2+433%— | 4.2+433%— | 2.1+238%— | 19+128%— | — | 0.8r16−86.8%— | 0.6r13−89.1%— | 8.5+46.9%— | — | 5.9—— | 5.8—— | 5.8—— | — | |
| Shares, weighted average (diluted) | 4.2+433%— | 4.2+433%— | 2.1+238%— | 19+128%— | — | 0.8r16−86.8%— | 0.6r13−89.1%— | 8.5+46.9%— | — | 5.9—— | 5.8—— | 5.8—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 5.0—26.7% | 5.0−44.6%26.7% | 5.1−50.0%26.7% | 15−26.0%50.5% | 5.1−74.7%25.3% | 9.1−56.6%32.7% | 10+1.4%34.7% | 20−32.3%51.6% | 20−25.1%48.5% | 21—49.1% | 10.0—19.8% | 30—48.3% | 27—34.5% | |
| Short-term investments | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 18—36.4% | 11—17.4% | 30—38.4% | |
| Receivables | — | — | — | — | 0−100%0.0% | 3.2+8.9%11.7% | 2.8+8.1%9.4% | 2.3+7.5%5.9% | 3.3+19.9%8.1% | 3.0—7.0% | 2.5—5.1% | 2.2—3.5% | 2.8—3.6% | |
| Other current assets | 1.4—7.2% | 1.4−15.8%7.2% | 1.1−27.6%5.8% | 1.6−27.3%5.4% | 1.9−39.0%9.3% | 1.6−48.1%5.8% | 1.5−57.7%5.2% | 2.2−30.6%5.6% | 3.0+70.7%7.4% | 3.1—7.3% | 3.6—7.2% | 3.2—5.1% | 1.8—2.3% | |
| Current assets | 6.9—36.8% | 6.9−50.3%36.8% | 6.7−53.4%35.4% | 17−33.0%56.0% | 6.9−73.8%34.6% | 14−48.4%50.3% | 14−58.2%49.3% | 25−46.1%63.1% | 26−56.7%63.9% | 27—63.4% | 35—68.5% | 46—74.3% | 61—78.8% | |
| Property, plant and equipment | 0.0—0.2% | 0.0−63.3%0.2% | 0.0−64.6%0.2% | 0.1−68.6%0.2% | 0.1−73.2%0.3% | 0.1−60.2%0.4% | 0.1−57.8%0.4% | 0.2−53.5%0.4% | 0.2−46.8%0.6% | 0.2—0.6% | 0.3—0.6% | 0.4—0.6% | 0.4—0.6% | |
| Right-of-use (leased) assets | 0.9—4.5% | 0.9−61.6%4.5% | 1.2−52.6%6.4% | 1.6−45.7%5.2% | 1.9−40.2%9.5% | 2.2−35.8%8.0% | 2.5−32.2%8.7% | 2.9+5.7%7.3% | 3.2+3.5%7.7% | 3.5—8.1% | 3.8—7.4% | 2.7—4.4% | 3.1—4.0% | |
| Goodwill | 9.0—47.8% | 9.00.0%47.8% | 9.00.0%47.3% | 9.00.0%30.3% | 9.00.0%45.0% | 9.00.0%32.5% | 9.00.0%30.7% | 9.00.0%22.8% | 9.00.0%21.8% | 9.0—21.1% | 9.0—17.8% | 9.0—14.5% | 9.0—11.6% | |
| Total assets | 19—100% | 19−32.0%100% | 19−35.1%100% | 30−24.5%100% | 20−51.6%100% | 28−34.9%100% | 29−42.0%100% | 39−36.6%100% | 41−46.6%100% | 42—100% | 50—100% | 62—100% | 77—100% | |
| Accounts payable | 7.5—39.7% | 7.5+68.1%39.7% | 5.4+31.5%28.4% | 6.7+32.1%22.7% | 5.6+85.6%28.1% | 4.4+16.4%16.1% | 4.1+67.3%14.0% | 5.1+40.7%13.0% | 3.0−4.7%7.3% | 3.8—9.0% | 2.4—4.9% | 3.6—5.8% | 3.2—4.1% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 7.0—25.1% | 7.4—25.2% | 7.2—18.4% | 7.6−11.1%18.3% | — | — | — | 8.5—11.0% | |
| Current liabilities | 16—86.4% | 16−18.4%86.4% | 14−29.4%72.1% | 15−25.6%50.4% | 14−26.0%70.5% | 20−9.6%72.0% | 19+0.0%66.3% | 20+78.0%51.2% | 19−13.6%46.1% | 22—51.9% | 19—38.4% | 11—18.2% | 22r14—28.5% | |
| Lease liabilities (non-current) | — | — | 0−100%0.0% | 0.1−91.9%0.4% | 0.4−73.5%2.1% | 0.7−62.4%2.7% | 1.0−54.8%3.6% | 1.3+17.7%3.4% | 1.6+8.7%3.9% | 2.0—4.6% | 2.3—4.6% | 1.1—1.8% | 1.5—1.9% | |
| Total liabilities | 16—86.4% | 16−61.6%86.4% | 14−67.0%75.3% | 17−63.0%57.2% | 15−69.3%72.6% | 42−17.3%153% | 43−15.4%148% | 46−12.6%117% | 47−18.0%115% | 51—121% | 51—101% | 53—84.7% | 58—74.5% | |
| Retained earnings | −1,288—−6853% | −1,288—−6853% | −1,280—−6748% | −1,272—−4283% | −1,247—−6248% | −1,267—−4583% | −1,259—−4307% | −1,250—−3180% | −1,240—−3004% | −1,230—−2896% | −1,220—−2420% | −1,208—−1948% | −1,196—−1548% | |
| Shareholders' equity | 2.6—13.6% | 2.6—13.6% | 4.7—24.7% | 13—42.8% | 5.5—27.4% | −15—−53.1% | −14—−47.8% | −6.6−170%−16.8% | −6.0−130%−14.5% | −8.7—−20.6% | −0.7—−1.4% | 9.5—15.3% | 20—25.5% | |
| Total liabilities and equity | 19—100% | 19−32.0%100% | 19−35.1%100% | 30−24.5%100% | 20−51.6%100% | 28−34.9%100% | 29−42.0%100% | 39−36.6%100% | 41−46.6%100% | 42—100% | 50—100% | 62—100% | 77—100% | |
| Shares outstanding | 4.1—— | 4.1−67.8%— | 1.9−81.8%— | 40+282%— | 0.6r13−92.4%— | 13+112%— | 11+81.4%— | 10+77.5%— | 8.5+44.0%— | 6.0—— | 5.9—— | 5.9—— | 5.9—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | 0.0*−81.0%— | 0.0−86.4%— | 0.0*+125%3.2% | 0.0*−47.5%1.0% | 0.0*−32.3%1.5% | 0.1−7.8%2.5% | 0.0*−75.0%0.5% | 0.1*—2.1% | 0.1*—2.4% | 0.1—3.1% | 0.1*—2.4% | |
| Share-based compensation | 2.5−45.3%— | 0.5−43.1%— | 0.6−49.9%— | 0.6−50.6%— | 0.8*−37.9%69.9% | 0.9−33.2%29.1% | 1.1−33.4%41.3% | 1.2−25.3%48.9% | 1.3*−17.3%38.3% | 1.4—47.2% | 1.7—66.9% | 1.6—74.7% | 1.5*—57.4% | |
| Cash from operating activities | −31—— | −5.7*—— | −9.6*—— | −9.0—— | −6.4*—−560% | −5.6*—−175% | −8.0*—−291% | −7.3—−305% | −9.3*—−277% | −5.9*—−203% | −11*—−437% | −13—−634% | −10*—−378% | |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from investing activities | — | — | 0*—— | 0—— | 2.5*—220% | 0*−100%0.0% | 0*—0.0% | 0−100%0.0% | −0.4*−103%−12.8% | 18*—625% | −7.4*—−289% | 19—907% | 15*—538% | |
| Shares issued | — | — | −0.3*—— | 19+89.4%— | −0.1*−101%−10.5% | 6.0*+769%190% | −0.6*−299%−21.0% | 10—420% | 11*+9253%330% | 0.7*—23.7% | 0.3*—11.4% | 0—0.0% | 0.1r14*—4.4% | |
| Cash from financing activities | 24+29.5%— | 5.7*+27.0%— | −0.3*—— | 19+151%— | −0.1*−101%−10.5% | 4.5*—141% | −2.1*—−77.7% | 7.5—317% | 8.8*—264% | −1.5*—−52.0% | −1.5*—−57.5% | −2.4—−115% | −2.1*—−78.6% | |
| Change in cash | −4.0—— | −0.1*—— | −9.9*—— | 9.9+3388%— | −4.0*—−351% | −1.1*−110%−34.2% | −10*—−369% | 0.3−91.3%12.0% | −0.9*−139%−25.6% | 11*—370% | −20*—−784% | 3.3—157% | 2.2*—82.1% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Curis, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 6 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 4 · Agreement ended 1 · Unregistered share sale 4 · Shareholder rights changed 4 · Bylaws or fiscal year changed 7 · Shareholder vote 4 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changed | 8-K/A | |
| Shareholder vote | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Acquisition or sale completedAgreement endedResults announced | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officersShareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
H-1B hiring at Curis, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $205 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Clinical SciencesMedical Scientists, Except Epidemiologists | 1 | $205 K |
Where: Lexington, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 1 | 1 | $205 K | 1 |
| FY2024 | 2 | 2 | $234 K | 2 |
| FY2022 | 2 | 2 | $175 K | 2 |
| FY2021 | 1 | 1 | $225 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Curis, Inc.
How Curis, Inc. compares in Biotechnology
- Market cap$5 M · higher than 6% of 726
- Revenue$9 M · higher than 42% of 647
- Net margin-80.3% · higher than 44% of 408
- Revenue growth-13.5% · higher than 32% of 438
- Price / sales0.6× · lower than 97% of 339
- Price / book1.0× · lower than 80% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Curis, Inc.🇺🇸 | $5 M | — | -80.3% | -13.5% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Curis, Inc.? Verify and update this profile — free
Show Curis, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.